Descrizione del progetto
Progressi nella terapia protonica per il trattamento del cancro
La terapia protonica è la forma più efficiente di radioterapia in cui protoni ad alta energia distruggono le cellule tumorali. Essa può essere utilizzata come trattamento principale o in combinazione con l’intervento chirurgico, la chemioterapia o l’immunoterapia. La terapia protonica è un’opzione importante, in particolare nei casi in cui i tumori non possono essere completamente asportati con l’intervento chirurgico. Tuttavia, questa opzione di trattamento viene limitata dalla dimensione e dal costo dei sistemi: oggi esistono solo 66 strutture operative per la terapia protonica al mondo, che coprono circa il 5 % della domanda. I finanziamenti dell’UE sosterranno lo sviluppo industriale di un sistema per la terapia protonica ad elevate prestazioni ultra compatto. Ciò avverrà con l’ottimizzazione dell’acceleratore laser di protoni e la convalida clinica delle prestazioni laser protoniche per fornire un dispositivo estremamente conveniente.
Obiettivo
Cancer is a global problem with 14.1 million new cases occurring annually and an expected increase of 68% by 2030. Ensuring effective and safe treatment remains a significant challenge for healthcare organisations. Studies have shown proton therapy to be effective in treating many types of tumours, including tumours of the prostate, brain, head and neck, central nervous system, lung, and gastrointestinal system as well as cancers that cannot be removed completely by surgery. Proton therapy is the most advanced type of external-beam radiation therapy that uses protons at high energy to destroy cancer cells. Proton therapy can be used alone or combined with other treatments e.g. radiation therapy, surgery, chemotherapy, and/or immunotherapy. Proton therapy is routinely used for cancer treatment however it is limited by the sheer size and expense of the systems. There are currently only 66 operational proton therapy facilities in the world, addressing only 3-5% of clinical demand. HIL has developed an ultra-compact, high-performance system for Proton Therapy. HIL’s advanced particle accelerator and beamline technologies aim to make PT widely accessible by offering highly cost-effective single-room solutions. During the innovation project, HIL intends to scale-up the performance of the laser proton accelerator, customise the design of the delivery system, and clinically validate the laser proton performance. The project will also enable crucial commercial activities including implementation of IP strategy, communication strategy and scouting potential customers.
Campo scientifico
- natural sciencesbiological sciencesneurobiology
- natural sciencesphysical sciencestheoretical physicsparticle physicsparticle accelerator
- medical and health sciencesclinical medicinesurgery
- medical and health sciencesclinical medicineoncology
- medical and health sciencesbasic medicineimmunologyimmunotherapy
Parole chiave
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEInst-2018-2020-2
Meccanismo di finanziamento
SME-2 - SME instrument phase 2Coordinatore
9139000 Jerusalem
Israele
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.